<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Our objective was to study the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with severe <z:hpo ids='HP_0005549'>congenital neutropenia</z:hpo> <z:chebi fb="0" ids="29425">(SCN)</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Among 101 cases of <z:chebi fb="0" ids="18022">SCN</z:chebi> included in the French Severe <z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:hpo ids='HP_0001875'>Neutropenia</z:hpo> Registry, nine patients received HSCT between 1993 and 2003, in seven institutions </plain></SENT>
<SENT sid="2" pm="."><plain>The indications were nonresponse to G-CSF therapy in four cases, <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> in one case, and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> or <z:hpo ids='HP_0001909'>leukemia</z:hpo> in four cases </plain></SENT>
<SENT sid="3" pm="."><plain>The conditioning regimen consisted of total body irradiation in two cases and chemotherapy alone in the other seven cases </plain></SENT>
<SENT sid="4" pm="."><plain>Seven patients received stem cells from unrelated donors and two from identical siblings </plain></SENT>
<SENT sid="5" pm="."><plain>Engraftment occurred in <z:hpo ids='HP_0000001'>all</z:hpo> but one of the patients </plain></SENT>
<SENT sid="6" pm="."><plain>Three patients died </plain></SENT>
<SENT sid="7" pm="."><plain>The respective causes of <z:hpo ids='HP_0011420'>death</z:hpo> were <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e>, <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, and EBV post-transplant <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative disease</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Six patients are alive and in complete remission, with a median follow-up of 3.1 years </plain></SENT>
<SENT sid="9" pm="."><plain>These results indicate that HSCT is feasible for patients with <z:chebi fb="0" ids="18022">SCN</z:chebi> who do not respond to G-CSF, who have <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e>, or who are at a high risk of <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e>, even if an HLA-identical sibling donor is not available </plain></SENT>
</text></document>